10x Genomics (TXG) 10-Q 6 Aug 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Jul. 31, 2021
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-39035
Entity Registrant Name	10x Genomics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-5614458
Entity Address, Address Line One	6230 Stoneridge Mall Road
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	925
Local Phone Number	401-7300
Title of 12(b) Security	Class A common stock, par value $0.00001 per share
Trading Symbol	TXG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001770787
Common Class A
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		90,604,177
Common Class B
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		20,281,465

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 621,958	$ 663,603
Restricted cash	18,151	16,567
Accounts receivable, net	59,680	51,208
Inventory	44,087	29,959
Prepaid expenses and other current assets	13,298	13,029
Total current assets	757,174	774,366
Property and equipment, net	122,329	72,840
Restricted cash	8,599	8,474
Operating lease right-of-use assets	54,125	46,983
Goodwill	4,511	0
Other non-current assets	30,841	26,678
Total assets	977,579	929,341
Current liabilities:
Accrued contingent liabilities	29,496	44,173
Accounts payable	16,181	4,709
Accrued compensation and related benefits	21,113	15,383
Accrued expenses and other current liabilities	36,157	43,453
Deferred revenue	5,274	4,472
Operating lease liabilities	4,905	5,936
Total current liabilities	113,126	118,126
Accrued license fee, noncurrent	5,814	11,171
Operating lease liabilities, noncurrent	65,917	57,042
Other noncurrent liabilities	8,136	3,930
Total liabilities	192,993	190,269
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock	0	0
Common stock	2	2
Additional paid-in capital	1,612,227	1,544,218
Accumulated deficit	(827,701)	(805,098)
Accumulated other comprehensive gain (loss)	58	(50)
Total stockholders’ equity	784,586	739,072
Total liabilities and stockholders’ equity	$ 977,579	$ 929,341

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue	$ 115,842	$ 42,905	$ 221,663	$ 114,810
Cost of revenue	4,915	10,052	21,975	25,160
Gross profit	110,927	32,853	199,688	89,650
Operating expenses:
Research and development	53,402	27,535	95,285	53,527
Selling, general and administrative	68,703	44,416	125,607	94,803
Accrued contingent liabilities	(850)	322	(660)	624
Total operating expenses	121,255	72,273	220,232	148,954
Loss from operations	(10,328)	(39,420)	(20,544)	(59,304)
Other income (expense):
Interest income	58	125	108	1,443
Interest expense	(209)	(306)	(430)	(968)
Other income (expense), net	521	(144)	(208)	(240)
Loss on extinguishment of debt	0	0	0	(1,521)
Total other income (expense)	370	(325)	(530)	(1,286)
Loss before provision for income taxes	(9,958)	(39,745)	(21,074)	(60,590)
Provision for income taxes	1,094	422	1,529	720
Net loss	(11,052)	(40,167)	(22,603)	(61,310)
Other comprehensive income:
Foreign currency translation adjustment	10	355	108	360
Comprehensive loss	$ (11,042)	$ (39,812)	$ (22,495)	$ (60,950)
Net loss per share, basic (in dollars per share)	$ (0.10)	$ (0.41)	$ (0.21)	$ (0.63)
Net loss per share, diluted (in dollars per share)	$ (0.10)	$ (0.41)	$ (0.21)	$ (0.63)
Weighted-average shares of common stock used in computing net loss per share, basic (in shares)	109,866,294	98,978,283	109,293,342	97,903,687
Weighted-average shares of common stock used in computing net loss per share, diluted (in shares)	109,866,294	98,978,283	109,293,342	97,903,687

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Common Class A	Common Class ACommon Stock	Common Class AAdditional Paid-in Capital
Beginning balance (in shares) at Dec. 31, 2019		96,241,596
Beginning balance at Dec. 31, 2019	$ 420,083	$ 2	$ 682,494	$ (262,367)	$ (46)
Issuance of Class A common stock upon exercise of stock options (in shares)							1,903,612
Issuance of Class A common stock upon exercise of stock options						$ 3,283		$ 3,283
Vesting of shares subject to repurchase, including early exercised options	122		122
Stock-based compensation	6,718		6,718
Net loss	(21,143)			(21,143)
Other comprehensive income	5				5
Ending balance (in shares) at Mar. 31, 2020		98,145,208
Ending balance at Mar. 31, 2020	409,068	$ 2	692,617	(283,510)	(41)
Beginning balance (in shares) at Dec. 31, 2019		96,241,596
Beginning balance at Dec. 31, 2019	420,083	$ 2	682,494	(262,367)	(46)
Net loss	(61,310)
Ending balance (in shares) at Jun. 30, 2020		100,259,182
Ending balance at Jun. 30, 2020	391,269	$ 2	714,630	(323,677)	314
Beginning balance (in shares) at Mar. 31, 2020		98,145,208
Beginning balance at Mar. 31, 2020	409,068	$ 2	692,617	(283,510)	(41)
Issuance of Class A common stock upon exercise of stock options (in shares)							2,113,974
Issuance of Class A common stock upon exercise of stock options						8,051		8,051
Vesting of shares subject to repurchase, including early exercised options	42		42
Stock-based compensation	13,920		13,920
Net loss	(40,167)			(40,167)
Other comprehensive income	355				355
Ending balance (in shares) at Jun. 30, 2020		100,259,182
Ending balance at Jun. 30, 2020	391,269	$ 2	714,630	(323,677)	314
Beginning balance (in shares) at Dec. 31, 2020		108,485,909
Beginning balance at Dec. 31, 2020	739,072	$ 2	1,544,218	(805,098)	(50)
Issuance of Class A common stock upon exercise of stock options (in shares)							1,102,618
Issuance of Class A common stock upon exercise of stock options						8,546		8,546
Vesting of shares subject to repurchase, including early exercised options	42		42
Stock-based compensation	16,253		16,253
Net loss	(11,551)			(11,551)
Other comprehensive income	98				98
Ending balance (in shares) at Mar. 31, 2021		109,588,527
Ending balance at Mar. 31, 2021	752,460	$ 2	1,569,059	(816,649)	48
Beginning balance (in shares) at Dec. 31, 2020		108,485,909
Beginning balance at Dec. 31, 2020	$ 739,072	$ 2	1,544,218	(805,098)	(50)
Issuance of Class A common stock upon exercise of stock options (in shares)	2,054,260
Net loss	$ (22,603)
Ending balance (in shares) at Jun. 30, 2021		110,739,919
Ending balance at Jun. 30, 2021	784,586	$ 2	1,612,227	(827,701)	58
Beginning balance (in shares) at Mar. 31, 2021		109,588,527
Beginning balance at Mar. 31, 2021	752,460	$ 2	1,569,059	(816,649)	48
Issuance of Class A common stock upon exercise of stock options (in shares)							1,151,392
Issuance of Class A common stock upon exercise of stock options						$ 16,194		$ 16,194
Vesting of shares subject to repurchase, including early exercised options	42		42
Stock-based compensation	26,932		26,932
Net loss	(11,052)			(11,052)
Other comprehensive income	10				10
Ending balance (in shares) at Jun. 30, 2021		110,739,919
Ending balance at Jun. 30, 2021	$ 784,586	$ 2	$ 1,612,227	$ (827,701)	$ 58

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities:
Net loss	$ (22,603)	$ (61,310)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	9,641	6,502
Stock-based compensation expense	43,108	20,573
Loss on disposal of property and equipment	66	1
Loss on extinguishment of debt	0	1,521
Accretion of discount on term loan	0	17
Amortization of right-of-use assets	4,014	2,226
Changes in operating assets and liabilities:
Accounts receivable	(7,824)	10,646
Inventory	(14,215)	(6,488)
Prepaid expenses and other current assets	(1,070)	(1,706)
Other assets	217	(2,966)
Accounts payable	9,711	(2,810)
Accrued compensation and other related benefits	5,730	(2,097)
Deferred revenue	952	492
Accrued contingent liabilities	(14,676)	6,518
Accrued expenses and other current liabilities	(6,530)	3,100
Operating lease liability	(3,170)	(1,986)
Other noncurrent liabilities	(4,313)	(4,327)
Net cash used in operating activities	(962)	(32,094)
Investing activities:
Acquisition of business, net of cash acquired	(5,451)	0
Purchases of property and equipment	(53,433)	(14,818)
Net cash used in investing activities	(58,884)	(14,818)
Financing activities:
Payments on financing arrangement	(5,028)	(5,846)
Payments on term loans	0	(31,256)
Issuance of common stock from exercise of stock options and employee stock purchase plan purchases	24,739	11,334
Net cash provided by (used in) financing activities	19,711	(25,768)
Effect of exchange rates on changes in cash, cash equivalents, and restricted cash	199	(123)
Net decrease in cash, cash equivalents, and restricted cash	(39,936)	(72,803)
Cash, cash equivalents, and restricted cash at beginning of period	688,644	476,493
Cash, cash equivalents, and restricted cash at end of period	648,708	403,690
Supplemental disclosures of cash flow information:
Cash paid for interest	1,222	1,670
Cash paid for taxes	7,838	160
Noncash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	7,516	2,454
Right-of-use assets obtained in exchange for new operating lease liabilities	11,267	7,558
Contingent consideration payable from business acquisition	$ 1,523	$ 0

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Organization and Description of Business 10x Genomics, Inc. (the “Company”) was incorporated in the state of Delaware on July 2, 2012 and is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company’s integrated solutions include the Company’s Chromium Controller, Chromium Connect and Chromium X Series instruments, which the Company refers to as “instruments,” and the Company’s proprietary microfluidic chips, slides, reagents and other consumables for both the Company’s Visium and Chromium solutions, which the Company refers to as “consumables.” The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The Company began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in Canada, China, Denmark, Germany, Netherlands, Singapore, Sweden, the United States and the United Kingdom. Basis of Presentation The accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2020 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates. The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the SEC on February 26, 2021 (our "Annual Report").

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Fair Value of Financial Instruments Cash and cash equivalents are comprised of money market funds and cash which are classified as Level 1 in the fair value hierarchy. As of June 30, 2021 and December 31, 2020, the Company held $547.9 million and $600.9 million in money market funds, respectively, with no unrealized gains or losses. Revenue Recognition The Company generates revenue from sales of products and services and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component. The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts. Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities, including convertible preferred stock and awards under the Company’s equity compensation plans. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.

Acquisition

Acquisition	6 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Acquisition	Acquisition On January 8, 2021 (the "acquisition date"), the Company purchased 100% of the outstanding shares of Tetramer Shop ApS (“Tetramer Shop”), a privately held company based in Copenhagen, Denmark, for a total cash consideration of $8.5 million, net of cash acquired of $0.2 million and including $1.5 million of estimated fair value of contingent consideration. The contingent consideration is recorded as a liability and is payable upon the successful transfer of Tetramer Shop's technology to the Company within two years of the acquisition date. Tetramer Shop is a life sciences technology company which develops and provides reagents for precise monitoring of antigen-specific T-cells in research and development. The Company acquired Tetramer Shop for its expertise in building empty, loadable major histocompatibility complex (MHC) molecules. The acquisition was accounted for using the acquisition method of accounting, with Tetramer Shop treated as the acquiree. The acquired assets and liabilities were recorded at their respective fair values including an amount for goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets. Our condensed consolidated statements of income include the financial results of Tetramer Shop subsequent to the acquisition date. Revenue related to Tetramer Shop since the acquisition date was included in our condensed consolidated statements of income and was not material. The acquisition price was allocated to the tangible and identified intangible assets acquired and liabilities assumed as of the acquisition date based upon their respective fair values. The fair values assigned to assets acquired and liabilities assumed were based on management’s assumptions as of the reporting date. The estimated fair value of assets acquired, including goodwill and intangibles, and liabilities assumed as of the acquisition date were as follows (in thousands): Amount Cash and cash equivalents $ 224 Other current assets 45 Property and equipment, net 38 Tangible assets acquired 307 Accrued expenses (555) Other current liabilities (97) Deferred tax liability - non-current (1,131) Total net tangible assets acquired and liabilities assumed (1,476) Intangible assets 5,640 Goodwill 4,511 Net assets acquired $ 8,675 The intangible assets as of the acquisition date included (in thousands): Amount Weighted Average Useful Life (in years) Developed technology $ 5,500 10 Customer relationships 140 3 $ 5,640 The fair value of the intangible assets acquired in connection with the acquisition was determined using either the income or replacement cost methodologies. The developed technology and customer relationships will be amortized over ten years and three years, respectively. Identifiable Intangible Assets Valuation of intangible assets involves multiple assumptions. The key assumptions are described below. Developed technology acquired primarily consists of existing technology related to developing reagents for precise monitoring of antigen-specific T cells in research and development, enabling the Company to strengthen its efforts in immunology. The Company valued the developed technology using the multi-period excess earnings method under the income approach. Using this approach, the estimated fair values were calculated using expected future cash flows discounted to their net present values at an appropriate risk-adjusted rate of return. Goodwill

Other Financial Statement Infor

Other Financial Statement Information	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Financial Statement Information	Other Financial Statement Information Inventory Inventory was comprised of the following (in thousands): June 30, December 31, Purchased materials $ 19,375 $ 9,930 Work in progress 12,316 9,312 Finished goods 12,396 10,717 Inventory $ 44,087 $ 29,959 Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): June 30, December 31, Land $ 31,798 $ — Laboratory equipment and machinery 38,221 30,010 Computer equipment and software 11,448 5,783 Furniture and fixtures 5,586 5,887 Leasehold improvements 48,872 42,068 Construction in progress 25,615 19,594 Total property and equipment 161,540 103,342 Less: accumulated depreciation and amortization (39,211) (30,502) Property and equipment, net $ 122,329 $ 72,840 Intangible Assets, Net Intangible assets, net, which are recorded within other assets in the condensed consolidated balance sheets, consisted of the following (dollars in thousands): June 30, 2021 December 31, 2020 Remaining Useful Life in Years Gross Accumulated Intangibles, Remaining Useful Life in Years Gross Accumulated Intangibles, Technology licenses 13.2 $ 22,504 $ (2,739) $ 19,765 13.7 $ 22,504 $ (1,973) $ 20,531 Developed technology 9.5 5,500 (275) 5,225 — — — — Customer relationships 3.3 945 (224) 721 3.9 805 (111) 694 Trademarks 0.4 204 (176) 28 0.9 204 (142) 62 Assembled workforce 4.3 1,128 (174) 954 4.8 1,128 (61) 1,067 Total intangible assets, net $ 30,281 $ (3,588) $ 26,693 $ 24,641 $ (2,287) $ 22,354 The estimated annual amortization of intangible assets for the next five years is shown below (in thousands): Estimated 2021 (excluding the six months ended June 30, 2021) $ 1,297 2022 2,535 2023 2,506 2024 2,378 2025 2,214 Thereafter 15,763 Total $ 26,693 Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures and asset impairments, among other factors. Accrued Compensation and Related Benefits Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): June 30, December 31, Accrued payroll and related costs $ 4,566 $ 2,506 Employee stock purchase program liability 1,492 1,258 Accrued bonus 7,922 5,058 Accrued commissions 3,310 3,038 Accrued acquisition-related compensation 1,847 2,213 Accrued vacation 1,322 1,035 Other 654 275 Accrued compensation and related benefits $ 21,113 $ 15,383 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): June 30, December 31, Accrued legal and related costs $ 5,305 $ 5,704 Accrued license fee 5,784 6,198 Accrued purchase consideration 4,901 4,146 Accrued royalties for licensed technologies 2,530 3,160 Accrued property and equipment 5,772 2,983 Accrued professional services 3,682 3,137 Product warranties 577 399 Customer deposits 1,098 1,727 Taxes payable 4,201 8,649 Accrued lab supplies 2,110 1,506 Other 197 5,844 Accrued expenses and other current liabilities $ 36,157 $ 43,453 Product Warranties Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): June 30, December 31, Beginning of period $ 399 $ 467 Amounts charged to cost of revenue 1,242 796 Repairs and replacements (1,064) (864) End of period $ 577 $ 399 Revenue and Deferred Revenue As of June 30, 2021, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of Chromium instruments, was $6.9 million, of which approximately 73% is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $6.9 million and $6.2 million as of June 30, 2021 and December 31, 2020, respectively, consisted of deferred revenue related to extended warranty service agreements, and as of June 30, 2021, the short-term portion was $5.1 million. Revenue recorded during the three and six months ended June 30, 2021 included $1.1 million and $2.5 million, respectively, of previously deferred revenue that was included in contract liabilities as of December 31, 2020. The following table represents revenue by source for the periods indicated (in thousands): Three Months Ended Six Months Ended 2021 2020 2021 2020 Instruments $ 16,877 $ 7,291 $ 28,002 $ 16,432 Consumables 97,146 34,164 190,225 95,592 Services 1,819 1,450 3,436 2,786 Total revenue $ 115,842 $ 42,905 $ 221,663 $ 114,810 The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended Six Months Ended 2021 2020 2021 2020 North America $ 65,765 $ 20,261 $ 117,572 $ 59,993 Europe, Middle East and Africa 28,772 11,715 47,942 24,873 China 12,874 7,628 36,514 18,625 Asia-Pacific (excluding China) 8,431 3,301 19,635 11,319 Total revenue $ 115,842 $ 42,905 $ 221,663 $ 114,810 Revenue for the United States, which is included in North America in the table above, was 52% and 45% of consolidated revenue for the three months ended June 30, 2021 and 2020, respectively, and 55% and 50% of consolidated revenue for the six months ended June 30, 2021 and 2020, respectively.

Debt

Debt	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Debt	Debt In September 2016, the Company entered into a Second Amended and Restated Loan and Security Agreement with Silicon Valley Bank (as amended and restated in February 2018 and as further amended, restated or supplemented from time to time, the “Loan and Security Agreement”), which included a term loan and revolving line of credit. On February 20, 2020, the Company prepaid the remaining balance of the term loan and all associated costs. The final payment of $30.5 million included $28.3 million for the outstanding principal balance of the term loan, $1.8 million for an end of term payment, $0.3 million for early termination fees and $0.1 million for interest. The prepayment resulted in a loss on extinguishment of debt of $1.5 million. The non-accreted portion of the end of term payment, unamortized discounts and early termination fees were included in the calculation of the loss on extinguishment of debt. The revolving line of credit and the Loan and Security Agreement was terminated at the election of the Company on June 18, 2020. Upon termination, the Company incurred termination fees of $0.3 million. As of June 18, 2020, there were no balances outstanding under the revolving line of credit.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease Agreements The Company leases office, laboratory, manufacturing, distribution and server space with lease terms up to 12 years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. For the three and six months ended June 30, 2021, the Company incurred $2.6 million and $5.2 million, respectively, of operating lease costs and $0.3 million and $0.4 million, respectively, of variable lease costs. For the three and six months ended June 30, 2020, the Company incurred $2.1 million and $4.0 million, respectively, of operating lease costs and $0.1 million and $0.2 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. Cash paid for amounts included in the measurement of operating lease liabilities for the six months ended June 30, 2021 and 2020 was $4.7 million and $3.1 million and were included in net cash used in operating activities in the Company’s condensed consolidated statements of cash flows. Future lease payments related to the Company’s operating lease liabilities as of June 30, 2021 is as follows (in thousands): Operating Leases 2021 (excluding the six months ended June 30, 2021) $ 1,262 2022 10,634 2023 10,414 2024 9,682 2025 9,853 Thereafter 48,771 Total lease payments $ 90,616 Less: imputed interest (19,794) Present value of operating lease liabilities $ 70,822 Operating lease liabilities, current $ 4,905 Operating lease liabilities, noncurrent $ 65,917 The following table summarizes additional information related to operating leases as of June 30, 2021: June 30, 2021 December 31, 2020 Weighted-average remaining lease term 8.7 years 8.4 years Weighted-average discount rate 5.3 % 4.5 % On November 6, 2020, the Company entered into a Master Lease Agreement ("MLA") to lease additional office building space near the Company's Pleasanton, California headquarters. The Company intends to utilize the leased space of approximately 145,000 square feet to accommodate its future growth requirements. The MLA consists of various lease components expected to commence on various dates between 2021 and 2023 and is expected to terminate on June 30, 2033 with total lease payments over the lease term expected to amount to approximately $60.8 million, net of a tenant improvement allowance of approximately $10.0 million to be received in the second half of 2021. Certain lease components of the MLA commenced on January 1, 2021. The total undiscounted lease payments for the lease components commencing during the remaining portion of fiscal year 2021 is $15.5 million with a weighted average lease term of 12 years. Total undiscounted payments for leases commencing in fiscal years 2022 and 2023 will be $21.0 million and $14.0 million, respectively, with weighted-average expected lease terms of 12 years for 2022 and 11 years for 2023. On April 30, 2021, the Company entered into a lease agreement to lease office building space of approximately 22,000 square feet in Stockholm, Sweden to accommodate its future growth requirements. The Company expects the lease term to commence in January 2022 for a five-year term and expects total lease payments over the lease term to amount to approximately $5.6 million. The tables above do not include payments, lease term, or discount rates relating to any leases or lease components that have not yet commenced as of June 30, 2021. The Company will determine the classification for each lease component at the individual component's commencement date. All leases and lease components that have not yet commenced are expected to be classified as operating leases. Lease payments for leases not yet Commenced 2021 (excluding the six months ended June 30, 2021) $ — 2022 1,640 2023 4,081 2024 5,603 2025 5,481 Thereafter 39,309 Total undiscounted lease payments $ 56,114 Litigation The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. The 2021 Bio-Rad Settlement And Patent Cross License Agreement Bio-Rad Laboratories, Inc. (“Bio-Rad”) and the Company were previously engaged in litigation and other proceedings relating to substantially all of the Company’s Chromium products, including the Company’s legacy GEM products and Next GEM products and multiple Bio-Rad products, around the world (the "Bio-Rad Actions"). On July 26, 2021, the Company entered into a Settlement and Patent Cross License Agreement (the “Agreement”) with Bio-Rad resolving all outstanding litigation and other proceedings between the two companies across all jurisdictions around the world and dismissing all infringement claims with prejudice. Pursuant to the terms of the Agreement, Bio-Rad and the Company granted each other a non-exclusive, worldwide, royalty-bearing license to develop products and services related to single cell analysis. The cross license excludes spatial and In Situ products. It also excludes digital PCR products in the case of 10x. The term of the Agreement is for the life of the licensed patents. The Company and Bio-Rad have agreed not to sue each other on licensed products and licensed services on other patents owned or exclusively licensed by each company. The companies have agreed that each company’s patents are owned by each respective company. Each company shall pay to the other royalties from licensed products and licensed services through 2030. The Company previously accrued $44.8 million in royalties and interest between November 14, 2018 and March 31, 2021 related to sales of the Company’s GEM products as a result of the litigation with Bio-Rad. Pursuant to the Agreement, the Company shall pay Bio-Rad $29.4 million in royalties and interest related to the sales of such GEM products between November 14, 2018 and March 31, 2021. As a result, in connection with the Agreement the Company reversed $15.4 million in accrued royalties and interest to the Company's financial statements in the second quarter of 2021. The Nanostring Action On May 6, 2021, the Company filed suit against Nanostring Technologies, Inc. ("Nanostring") in the U.S. District Court for the District of Delaware alleging that Nanostring's GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113, and 10,996,219. On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On July 1, 2021, Nanostring filed a motion to dismiss. Briefing is in progress and no hearing has been scheduled. Discovery has not yet commenced and no case schedule has been set. For further discussion of the risks relating to intellectual property and our pending litigation, see the section titled “Risk Factors—Risks related to litigation and our intellectual property” under Item 1A below.

Capital Stock

Capital Stock	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Capital Stock	Capital StockAs of June 30, 2021, the number of shares of Class A common stock and Class B common stock issued and outstanding was 90,458,454 and 20,281,465, respectively. During the three months ended June 30, 2021 and 2020, 2,250,000 and 13,630,921, respectively, and during the six months ended June 30, 2021 and 2020, 2,400,000 and 45,404,934, respectively, shares of Class B common stock, respectively, were converted to shares of Class A common stock upon the election of the holders of such shares.

Equity Incentive Plans

Equity Incentive Plans	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Equity Incentive Plans	Equity Incentive Plans 2019 Employee Stock Purchase Plan A total of 3,084,859 shares of Class A common stock was reserved for issuance under the 2019 Employee Stock Purchase Plan ("ESPP"). The price at which Class A common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. Shares purchased under the ESPP are subject to a one-year holding period following the purchase date. During the three months ended June 30, 2021 and 2020, 30,868 and 118,218 shares of Class A common stock, respectively, were issued under the ESPP. As of June 30, 2021, there were 2,890,264 shares available for issuance in connection under the ESPP. Stock-based Compensation The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended Six Months Ended 2021 2020 2021 2020 Cost of revenue $ 841 $ 463 $ 1,305 $ 710 Research and development 12,140 6,044 18,936 8,931 Selling, general and administrative 13,951 7,348 22,867 10,932 Total stock-based compensation expense $ 26,932 $ 13,855 $ 43,108 $ 20,573 Restricted Stock Units Restricted stock unit activity for the six months ended June 30, 2021 is as follows: Restricted Stock Weighted-Average Outstanding as of December 31, 2020 823,947 $ 80.97 Granted 726,026 186.42 Vested (168,632) 97.02 Cancelled (41,153) 108.34 Outstanding as of June 30, 2021 1,340,188 $ 135.24 Stock Options Stock option activity for the six months ended June 30, 2021 is as follows: Stock Options Weighted-Average Outstanding as of December 31, 2020 11,860,844 $ 18.86 Granted 349,996 178.61 Exercised (2,054,260) 10.37 Cancelled (114,418) 20.45 Outstanding as of June 30, 2021 10,042,162 $ 26.15

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended Six Months Ended 2021 2020 2021 2020 Stock-options to purchase common stock 10,042,162 13,507,230 10,042,162 13,507,230 Shares subject to repurchase 37,500 100,000 37,500 100,000 Contingent restricted shares 236,484 — 236,484 — Restricted stock units 1,340,188 702,610 1,340,188 702,610 Shares committed under ESPP 12,201 16,812 12,201 16,812 Total 11,668,535 14,326,652 11,668,535 14,326,652

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On July 26, 2021, the Company entered into a Settlement and Patent Cross License Agreement with Bio-Rad resolving all outstanding litigation and other proceedings between the two companies across all jurisdictions around the world and dismissing all infringement claims with prejudice. See Note 6 to condensed consolidated financial statements, Commitments and Contingencies, The 2021 Bio-Rad Settlement And Patent Cross License Agreement, for further details.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2020 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates.
Fair Value of Financial Instruments	Fair Value of Financial InstrumentsCash and cash equivalents are comprised of money market funds and cash which are classified as Level 1 in the fair value hierarchy.
Revenue Recognition	Revenue Recognition The Company generates revenue from sales of products and services and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component.
Net Loss Per Share	Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities, including convertible preferred stock and awards under the Company’s equity compensation plans. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.

Acquisition (Tables)

Acquisition (Tables)	6 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The estimated fair value of assets acquired, including goodwill and intangibles, and liabilities assumed as of the acquisition date were as follows (in thousands): Amount Cash and cash equivalents $ 224 Other current assets 45 Property and equipment, net 38 Tangible assets acquired 307 Accrued expenses (555) Other current liabilities (97) Deferred tax liability - non-current (1,131) Total net tangible assets acquired and liabilities assumed (1,476) Intangible assets 5,640 Goodwill 4,511 Net assets acquired $ 8,675
Schedule of Intangible Assets Acquired	The intangible assets as of the acquisition date included (in thousands): Amount Weighted Average Useful Life (in years) Developed technology $ 5,500 10 Customer relationships 140 3 $ 5,640

Other Financial Statement Inf_2

Other Financial Statement Information (Tables)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	Inventory was comprised of the following (in thousands): June 30, December 31, Purchased materials $ 19,375 $ 9,930 Work in progress 12,316 9,312 Finished goods 12,396 10,717 Inventory $ 44,087 $ 29,959
Schedule of Property, Plant and Equipment	Property and equipment, net consisted of the following (in thousands): June 30, December 31, Land $ 31,798 $ — Laboratory equipment and machinery 38,221 30,010 Computer equipment and software 11,448 5,783 Furniture and fixtures 5,586 5,887 Leasehold improvements 48,872 42,068 Construction in progress 25,615 19,594 Total property and equipment 161,540 103,342 Less: accumulated depreciation and amortization (39,211) (30,502) Property and equipment, net $ 122,329 $ 72,840
Schedule of Intangible Assets, Net	Intangible assets, net, which are recorded within other assets in the condensed consolidated balance sheets, consisted of the following (dollars in thousands): June 30, 2021 December 31, 2020 Remaining Useful Life in Years Gross Accumulated Intangibles, Remaining Useful Life in Years Gross Accumulated Intangibles, Technology licenses 13.2 $ 22,504 $ (2,739) $ 19,765 13.7 $ 22,504 $ (1,973) $ 20,531 Developed technology 9.5 5,500 (275) 5,225 — — — — Customer relationships 3.3 945 (224) 721 3.9 805 (111) 694 Trademarks 0.4 204 (176) 28 0.9 204 (142) 62 Assembled workforce 4.3 1,128 (174) 954 4.8 1,128 (61) 1,067 Total intangible assets, net $ 30,281 $ (3,588) $ 26,693 $ 24,641 $ (2,287) $ 22,354
Schedule of Annual Amortization of Intangible Assets	The estimated annual amortization of intangible assets for the next five years is shown below (in thousands): Estimated 2021 (excluding the six months ended June 30, 2021) $ 1,297 2022 2,535 2023 2,506 2024 2,378 2025 2,214 Thereafter 15,763 Total $ 26,693
Schedule of Accrued Compensation and Related Benefits	Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): June 30, December 31, Accrued payroll and related costs $ 4,566 $ 2,506 Employee stock purchase program liability 1,492 1,258 Accrued bonus 7,922 5,058 Accrued commissions 3,310 3,038 Accrued acquisition-related compensation 1,847 2,213 Accrued vacation 1,322 1,035 Other 654 275 Accrued compensation and related benefits $ 21,113 $ 15,383
Schedule of Accrued Expense and Other Current Liabilities	Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): June 30, December 31, Accrued legal and related costs $ 5,305 $ 5,704 Accrued license fee 5,784 6,198 Accrued purchase consideration 4,901 4,146 Accrued royalties for licensed technologies 2,530 3,160 Accrued property and equipment 5,772 2,983 Accrued professional services 3,682 3,137 Product warranties 577 399 Customer deposits 1,098 1,727 Taxes payable 4,201 8,649 Accrued lab supplies 2,110 1,506 Other 197 5,844 Accrued expenses and other current liabilities $ 36,157 $ 43,453
Schedule of Changes in the Reserve for Product Warranties	Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): June 30, December 31, Beginning of period $ 399 $ 467 Amounts charged to cost of revenue 1,242 796 Repairs and replacements (1,064) (864) End of period $ 577 $ 399
Schedule of Revenue by Source	The following table represents revenue by source for the periods indicated (in thousands): Three Months Ended Six Months Ended 2021 2020 2021 2020 Instruments $ 16,877 $ 7,291 $ 28,002 $ 16,432 Consumables 97,146 34,164 190,225 95,592 Services 1,819 1,450 3,436 2,786 Total revenue $ 115,842 $ 42,905 $ 221,663 $ 114,810
Schedule of Revenue by Geographic Location	The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended Six Months Ended 2021 2020 2021 2020 North America $ 65,765 $ 20,261 $ 117,572 $ 59,993 Europe, Middle East and Africa 28,772 11,715 47,942 24,873 China 12,874 7,628 36,514 18,625 Asia-Pacific (excluding China) 8,431 3,301 19,635 11,319 Total revenue $ 115,842 $ 42,905 $ 221,663 $ 114,810

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Summary of Company's Operating Lease Liabilities	Future lease payments related to the Company’s operating lease liabilities as of June 30, 2021 is as follows (in thousands): Operating Leases 2021 (excluding the six months ended June 30, 2021) $ 1,262 2022 10,634 2023 10,414 2024 9,682 2025 9,853 Thereafter 48,771 Total lease payments $ 90,616 Less: imputed interest (19,794) Present value of operating lease liabilities $ 70,822 Operating lease liabilities, current $ 4,905 Operating lease liabilities, noncurrent $ 65,917
Summary of Additional Information Related to Operating Leases	The following table summarizes additional information related to operating leases as of June 30, 2021: June 30, 2021 December 31, 2020 Weighted-average remaining lease term 8.7 years 8.4 years Weighted-average discount rate 5.3 % 4.5 %
Schedule of Estimated Undiscounted Lease Payments for Operating Lease, Lease Not Yet Commenced	Lease payments for leases not yet Commenced 2021 (excluding the six months ended June 30, 2021) $ — 2022 1,640 2023 4,081 2024 5,603 2025 5,481 Thereafter 39,309 Total undiscounted lease payments $ 56,114

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations	The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended Six Months Ended 2021 2020 2021 2020 Cost of revenue $ 841 $ 463 $ 1,305 $ 710 Research and development 12,140 6,044 18,936 8,931 Selling, general and administrative 13,951 7,348 22,867 10,932 Total stock-based compensation expense $ 26,932 $ 13,855 $ 43,108 $ 20,573
Summary of RSU activity	Restricted stock unit activity for the six months ended June 30, 2021 is as follows: Restricted Stock Weighted-Average Outstanding as of December 31, 2020 823,947 $ 80.97 Granted 726,026 186.42 Vested (168,632) 97.02 Cancelled (41,153) 108.34 Outstanding as of June 30, 2021 1,340,188 $ 135.24
Summary of the Company's Stock Option Activity	Stock option activity for the six months ended June 30, 2021 is as follows: Stock Options Weighted-Average Outstanding as of December 31, 2020 11,860,844 $ 18.86 Granted 349,996 178.61 Exercised (2,054,260) 10.37 Cancelled (114,418) 20.45 Outstanding as of June 30, 2021 10,042,162 $ 26.15

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended Six Months Ended 2021 2020 2021 2020 Stock-options to purchase common stock 10,042,162 13,507,230 10,042,162 13,507,230 Shares subject to repurchase 37,500 100,000 37,500 100,000 Contingent restricted shares 236,484 — 236,484 — Restricted stock units 1,340,188 702,610 1,340,188 702,610 Shares committed under ESPP 12,201 16,812 12,201 16,812 Total 11,668,535 14,326,652 11,668,535 14,326,652

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue recognition, payment due period	45 days
Fair Value, Inputs, Level 1 | Money Market Funds
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Fair value of money market instruments	$ 547.9	$ 600.9
Unrealized gains (losses) on money market instruments	$ 0	$ 0

Acquisition - Additional Inform

Acquisition - Additional Information (Details) - Tetramer Shop $ in Millions	Jan. 08, 2021USD ($)
Business Acquisition [Line Items]
Percentage of outstanding shares acquired	100.00%
Consideration transferred	$ 8.5
Cash acquired	0.2
Estimated fair value of contingent consideration	$ 1.5
Payment term	2 years
Developed technology
Business Acquisition [Line Items]
Weighted average useful life	10 years
Customer relationships
Business Acquisition [Line Items]
Weighted average useful life	3 years

Acquisition - Schedule of Asset

Acquisition - Schedule of Assets Acquired and Liabilities Assumed, Including Goodwill and Intangibles (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Jan. 08, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 4,511		$ 0
Tetramer Shop
Business Acquisition [Line Items]
Cash acquired		$ 224
Other current assets		45
Property and equipment, net		38
Tangible assets acquired		307
Accrued expenses		(555)
Other current liabilities		(97)
Deferred tax liability - non-current		(1,131)
Total net tangible assets acquired and liabilities assumed		(1,476)
Intangible assets		5,640
Goodwill		4,511
Net assets acquired		$ 8,675

Acquisition - Intangible Assets

Acquisition - Intangible Assets Acquired (Details) - Tetramer Shop $ in Thousands	Jan. 08, 2021USD ($)
Business Acquisition [Line Items]
Intangible assets	$ 5,640
Developed technology
Business Acquisition [Line Items]
Intangible assets	$ 5,500
Weighted Average Useful Life (in years)	10 years
Customer relationships
Business Acquisition [Line Items]
Intangible assets	$ 140
Weighted Average Useful Life (in years)	3 years

Other Financial Statement Inf_3

Other Financial Statement Information - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Purchased materials	$ 19,375	$ 9,930
Work in progress	12,316	9,312
Finished goods	12,396	10,717
Inventory	$ 44,087	$ 29,959

Other Financial Statement Inf_4

Other Financial Statement Information - Schedule Of Property Plant And Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 161,540	$ 103,342
Less: accumulated depreciation and amortization	(39,211)	(30,502)
Property and equipment, net	122,329	72,840
Land
Property, Plant and Equipment [Line Items]
Total property and equipment	31,798	0
Laboratory equipment and machinery
Property, Plant and Equipment [Line Items]
Total property and equipment	38,221	30,010
Computer equipment and software
Property, Plant and Equipment [Line Items]
Total property and equipment	11,448	5,783
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment	5,586	5,887
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	48,872	42,068
Construction in progress
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 25,615	$ 19,594

Other Financial Statement Inf_5

Other Financial Statement Information - Intangible Assets, Net (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 30,281	$ 24,641
Accumulated Amortization	(3,588)	(2,287)
Intangibles, Net	$ 26,693	$ 22,354
Technology licenses
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	13 years 2 months 12 days	13 years 8 months 12 days
Gross Carrying Amount	$ 22,504	$ 22,504
Accumulated Amortization	(2,739)	(1,973)
Intangibles, Net	$ 19,765	20,531
Developed technology
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	9 years 6 months
Gross Carrying Amount	$ 5,500	0
Accumulated Amortization	(275)	0
Intangibles, Net	$ 5,225	$ 0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	3 years 3 months 18 days	3 years 10 months 24 days
Gross Carrying Amount	$ 945	$ 805
Accumulated Amortization	(224)	(111)
Intangibles, Net	$ 721	$ 694
Trademarks
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	4 months 24 days	10 months 24 days
Gross Carrying Amount	$ 204	$ 204
Accumulated Amortization	(176)	(142)
Intangibles, Net	$ 28	$ 62
Assembled workforce
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	4 years 3 months 18 days	4 years 9 months 18 days
Gross Carrying Amount	$ 1,128	$ 1,128
Accumulated Amortization	(174)	(61)
Intangibles, Net	$ 954	$ 1,067

Other Financial Statement Inf_6

Other Financial Statement Information - Annual Amortization of Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
2021 (excluding the six months ended June 30, 2021)	$ 1,297
2022	2,535
2023	2,506
2024	2,378
2025	2,214
Thereafter	15,763
Intangibles, Net	$ 26,693	$ 22,354

Other Financial Statement Inf_7

Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and related costs	$ 4,566	$ 2,506
Employee stock purchase program liability	1,492	1,258
Accrued bonus	7,922	5,058
Accrued commissions	3,310	3,038
Accrued acquisition-related compensation	1,847	2,213
Accrued vacation	1,322	1,035
Other	654	275
Accrued compensation and related benefits	$ 21,113	$ 15,383

Other Financial Statement Inf_8

Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued legal and related costs	$ 5,305	$ 5,704
Accrued license fee	5,784	6,198
Accrued purchase consideration	4,901	4,146
Accrued royalties for licensed technologies	2,530	3,160
Accrued property and equipment	5,772	2,983
Accrued professional services	3,682	3,137
Product warranties	577	399
Customer deposits	1,098	1,727
Taxes payable	4,201	8,649
Accrued lab supplies	2,110	1,506
Other	197	5,844
Accrued expenses and other current liabilities	$ 36,157	$ 43,453

Other Financial Statement Inf_9

Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning of period	$ 399	$ 467
Amounts charged to cost of revenue	1,242	796
Repairs and replacements	(1,064)	(864)
End of period	$ 577	$ 399

Other Financial Statement In_10

Other Financial Statement Information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Concentration Risk [Line Items]
Transaction price allocated to remaining performance obligations	$ 6,900		$ 6,900
Contract liability	6,900		6,900		$ 6,200
Deferred revenue	5,274		5,274		$ 4,472
Contract with customer, liability, revenue recognized	1,100		2,500
Products and Services, Excluding Grant Revenue
Concentration Risk [Line Items]
Deferred revenue	$ 5,100		$ 5,100
Revenue | Geographic Concentration Risk | UNITED STATES
Concentration Risk [Line Items]
Percentage of revenue	52.00%	45.00%	55.00%	50.00%

Other Financial Statement In_11

Other Financial Statement Information - Revenue Recognition (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01	Jun. 30, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations percentage	73.00%
Expected period of revenue recognition	12 months

Other Financial Statement In_12

Other Financial Statement Information - Schedule of Revenue by Source (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue from External Customer [Line Items]
Revenue	$ 115,842	$ 42,905	$ 221,663	$ 114,810
Instruments
Revenue from External Customer [Line Items]
Revenue	16,877	7,291	28,002	16,432
Consumables
Revenue from External Customer [Line Items]
Revenue	97,146	34,164	190,225	95,592
Services
Revenue from External Customer [Line Items]
Revenue	$ 1,819	$ 1,450	$ 3,436	$ 2,786

Other Financial Statement In_13

Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 115,842	$ 42,905	$ 221,663	$ 114,810
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	65,765	20,261	117,572	59,993
Europe, Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	28,772	11,715	47,942	24,873
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	12,874	7,628	36,514	18,625
Asia-Pacific (excluding China)
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 8,431	$ 3,301	$ 19,635	$ 11,319

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 18, 2020	Feb. 20, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 0	$ 0	$ 0	$ (1,521)
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, termination fee	$ 300
Line of credit, outstanding	$ 0
Tranche A | Term Loan
Debt Instrument [Line Items]
Early payment of debt		$ 30,500
Early payment of debt principal amount		28,300
Early payment, term payment		1,800
Early payment of debt termination fees		300
Early payment of debt interest amount		100
Loss on extinguishment of debt		$ 1,500

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended		117 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2030USD ($)	Apr. 30, 2021USD ($)ft²	Mar. 31, 2021USD ($)	Nov. 06, 2020USD ($)ft²
Loss Contingencies [Line Items]
Operating lease costs	$ 2,600	$ 2,100	$ 5,200	$ 4,000
Variable lease costs	300	100	400	200
Operating lease payment			4,700	3,100
Reversal of accrued royalties and interest	850	$ (322)	660	$ (624)
Pleasanton, California
Loss Contingencies [Line Items]
Lease payment commencing the rest of the year	15,500		15,500
Lease payment commencing 2022	21,000		21,000
Lease payment commencing 2023	$ 14,000		$ 14,000
Pleasanton, California | Remainder of 2021
Loss Contingencies [Line Items]
Weighted-average expected lease terms	12 years		12 years
Pleasanton, California | 2022
Loss Contingencies [Line Items]
Weighted-average expected lease terms	12 years		12 years
Pleasanton, California | 2023
Loss Contingencies [Line Items]
Weighted-average expected lease terms	11 years		11 years
Additional office building
Loss Contingencies [Line Items]
Lease payment commencing 2022	$ 1,640		$ 1,640
Lease payment commencing 2023	4,081		4,081
Operating lease not yet commenced	56,114		$ 56,114
Additional office building | Pleasanton, California
Loss Contingencies [Line Items]
Real estate property, area | ft²								145,000
Expected total lease payments								$ 60,800
Tenant improvement allowance								$ 10,000
Additional office building | Stockholm, Sweden
Loss Contingencies [Line Items]
Real estate property, area | ft²						22,000
Weighted-average expected lease terms						5 years
Operating lease not yet commenced						$ 5,600
Bio RadLaboratories Inc
Loss Contingencies [Line Items]
Loss contingency							$ 44,800
Reversal of accrued royalties and interest	$ 15,400
Bio RadLaboratories Inc | Forecast
Loss Contingencies [Line Items]
Loss contingency payments					$ 29,400
Maximum
Loss Contingencies [Line Items]
Operating lease term	12 years		12 years

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Company's Operating Lease Liabilities (Detail) $ in Thousands	Jun. 30, 2021USD ($)
Operating Leases
2021 (excluding the six months ended June 30, 2021)	$ 1,262
2022	10,634
2023	10,414
2024	9,682
2025	9,853
Thereafter	48,771
Total lease payments	90,616
Less: imputed interest	(19,794)
Present value of operating lease liabilities	70,822
Operating lease liabilities, current	4,905
Operating lease liabilities, noncurrent	$ 65,917

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail)	Jun. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Weighted-average remaining lease term, operating leases	8 years 8 months 12 days	8 years 4 months 24 days
Weighted-average discount rate, operating leases	5.30%	4.50%

Commitments and Contingencies_4

Commitments and Contingencies - Estimated Undiscounted Lease Payments (Details) - Additional office building $ in Thousands	Jun. 30, 2021USD ($)
Lessee, Lease, Description [Line Items]
2021 (excluding the six months ended June 30, 2021)	$ 0
2022	1,640
Lease payment commencing 2023	4,081
2024	5,603
2025	5,481
Thereafter	39,309
Total undiscounted lease payments	$ 56,114

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Shares Converted From Class B to Class A
Class of Stock [Line Items]
Conversion of stock, shares converted (in shares)	2,250,000	13,630,921	2,400,000	45,404,934
Common Class A
Class of Stock [Line Items]
Common stock shares issued (in shares)	90,458,454		90,458,454
Common stock shares outstanding (in shares)	90,458,454		90,458,454
Common Class B
Class of Stock [Line Items]
Common stock shares issued (in shares)	20,281,465		20,281,465
Common stock shares outstanding (in shares)	20,281,465		20,281,465

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail) - Common Class A - 2019 Employee Stock Purchase Plan - Employee Stock - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)	2,890,264		2,890,264	3,084,859
Share-based compensation arrangement percent			85.00%
Holding period following purchase			1 year
Shares issued in period for previously outstanding awards (in shares)	30,868	118,218

Equity Incentive Plans - Record

Equity Incentive Plans - Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 26,932	$ 13,855	$ 43,108	$ 20,573
Cost of revenue
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	841	463	1,305	710
Research and development
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	12,140	6,044	18,936	8,931
Selling, general and administrative
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 13,951	$ 7,348	$ 22,867	$ 10,932

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of RSU Activity (Detail)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Restricted Stock Units, Beginning balance (in shares) | shares	823,947
Restricted Stock Units, Granted (in shares) | shares	726,026
Restricted Stock Units, Vested (in shares) | shares	(168,632)
Restricted Stock Units, Cancelled (in shares) | shares	(41,153)
Restricted Stock Units, Ending balance (in shares) | shares	1,340,188
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-Average Grant Date Fair Value, Beginning balance (in dollars per share) | $ / shares	$ 80.97
Weighted-Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares	186.42
Weighted-Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares	97.02
Weighted-Average Grant Date Fair Value, Cancelled (in dollars per share) | $ / shares	108.34
Weighted-Average Grant Date Fair Value, Ending balance (in dollars per share) | $ / shares	$ 135.24

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary of Company's Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding stock options, Beginning balance (in shares) | shares	11,860,844
Outstanding stock options - Granted (in shares) | shares	349,996
Outstanding stock options - Exercised (in shares) | shares	(2,054,260)
Outstanding stock options - Cancelled (in shares) | shares	(114,418)
Outstanding stock options, Ending balance (in shares) | shares	10,042,162
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted-average exercise price - Beginning balance (in dollars per share) | $ / shares	$ 18.86
Weighted-average exercise price - Granted (in dollars per share) | $ / shares	178.61
Weighted-average exercise price - Exercised (in dollars per share) | $ / shares	10.37
Weighted-average exercise price - Cancelled (in dollars per share) | $ / shares	20.45
Weighted-average exercise price - Ending balance (in dollars per share) | $ / shares	$ 26.15

Net Loss Per Share - Shares of

Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	11,668,535	14,326,652	11,668,535	14,326,652
Stock-options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	10,042,162	13,507,230	10,042,162	13,507,230
Shares subject to repurchase
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	37,500	100,000	37,500	100,000
Contingent restricted shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	236,484	0	236,484	0
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	1,340,188	702,610	1,340,188	702,610
Shares committed under ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	12,201	16,812	12,201	16,812